111 related articles for article (PubMed ID: 11395573)
1. (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice.
Misiura K; Kinas RW; Kuśnierczyk H; Radzikowski C; Stec WJ
Anticancer Drugs; 2001 Jun; 12(5):453-8. PubMed ID: 11395573
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
Glazman-Kuśnierczyk H; Matuszyk J; Radzikowski C
Immunopharmacol Immunotoxicol; 1992; 14(4):883-911. PubMed ID: 1294626
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, in vitro metabolic studies, and antitumour activity of methyl analogues of ifosfamide.
Misiura K; Kardacka K; Kusnierczyk H
Arch Pharm (Weinheim); 2001 Sep; 334(8-9):291-4. PubMed ID: 11688140
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide.
Sloderbach A; Hładoń B; Laskowska H
Acta Physiol Hung; 1996; 84(4):459-60. PubMed ID: 9328631
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
Misiura K; Kinas RW; Stec WJ; Kusnierczyk H; Radzikowski C; Sonoda A
J Med Chem; 1988 Jan; 31(1):226-30. PubMed ID: 3336021
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of potential metabolites of (S)-(-)-bromofosfamide.
Misiura K
Pharmazie; 2004 Sep; 59(9):668-72. PubMed ID: 15497745
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice.
Kobylińska K; Kobylińska M; Sobik B
Arzneimittelforschung; 2001; 51(7):596-9. PubMed ID: 11505792
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
Kuśnierczyk H; Matuszyk J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(5-6):547-56. PubMed ID: 2487366
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
Hładoń B; Sloderbach A; Laskowska H
Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
[TBL] [Abstract][Full Text] [Related]
10. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, stereochemistry and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and related compounds.
Takamizawa A; Matsumoto S; Iwata T; Makino I
Chem Pharm Bull (Tokyo); 1977 Aug; 25(8):1877-91. PubMed ID: 562722
[No Abstract] [Full Text] [Related]
12. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic action of a new analog of dacarbazine in mice bearing Lewis lung carcinoma.
Perissin L; Facchin P; Bedini A; Diamantini G; Tontini A; Tarzia G
Anticancer Res; 2000; 20(3A):1513-7. PubMed ID: 10928064
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.
Kusnierczyk H; Pajtasz-Piasecka E; Radzikowski C
Med Oncol; 1999 Dec; 16(4):267-78. PubMed ID: 10618690
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Zheng LM; Li Z; Liu L; Song BL; King I
Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
[TBL] [Abstract][Full Text] [Related]
17. Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
Misiura K; Kinas RW; Kuśnierczyk H
Bioorg Med Chem Lett; 2002 Feb; 12(3):427-31. PubMed ID: 11814813
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients.
Kobylińska K; Koralewski P; Sobik B; Gasiorek M; Kobylińska M
Arzneimittelforschung; 2001; 51(7):600-3. PubMed ID: 11505793
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cytostatic activity of the antitumor antibiotic chartreusin derivatives.
Kon K; Sugi H; Tamai K; Ueda Y; Yamada N
J Antibiot (Tokyo); 1990 Apr; 43(4):372-82. PubMed ID: 2351612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
